Onderneming Compugen Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
IL0010852080
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Therapeutic Products
100,0
%
| 8 | 100,0 % | 33 | 100,0 % | +346,12% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
70,1
%
| 0 | 0,0 % | 23 | 70,1 % | - |
Europe
29,9
%
| 8 | 100,0 % | 10 | 29,9 % | +33,33% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-01-02 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01-11-22 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Zurit Levine
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-01-99 |
Yvonne Naughton
IRC | Investor Relations Contact | - | 01-06-21 |
Eran Ben-Dor
LAW | General Counsel | - | 01-01-19 |
Dorit Amitay
HRO | Human Resources Officer | 56 | 01-01-99 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 02-10-17 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11-06-18 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11-06-18 |
Eran Perry
BRD | Director/Board Member | - | 01-07-17 |
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-01-02 |
Director/Board Member | 56 | 11-06-18 | |
Director/Board Member | 70 | 01-03-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 89 530 193 | 84 717 013 ( 94,62 %) | 0 | 94,62 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |